PriceTargets.com logo

Inozyme Pharma - INZY Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.00 As of 07/1/2025 01:00 AM ET
+0 (0.00%)
Get New Inozyme Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INZY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INZY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Inozyme Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.00.

This chart shows the closing price for INZY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Inozyme Pharma. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/16/2025TD CowenDowngradeStrong-Buy ➝ Hold
5/16/2025WedbushDowngradeStrong-Buy ➝ Hold
5/16/2025Needham & Company LLCDowngradeModerate Buy ➝ Hold
5/16/2025Wells Fargo & CompanyReiterated RatingOverweight ➝ Equal Weight$4.00
5/16/2025Jefferies Financial GroupReiterated RatingBuy ➝ Hold$15.00 ➝ $4.00
5/14/2025Needham & Company LLCLower TargetBuy ➝ Buy$15.00 ➝ $12.00
4/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/8/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/12/2025Raymond James FinancialLower TargetOutperform ➝ Outperform$24.00 ➝ $12.00
3/11/2025Piper SandlerLower TargetOverweight ➝ Overweight$30.00 ➝ $23.00
3/11/2025HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
3/11/2025Needham & Company LLCLower TargetBuy ➝ Buy$23.00 ➝ $15.00
3/10/2025WedbushReiterated RatingOutperform$12.00 ➝ $7.00
1/13/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$14.00 ➝ $11.00
1/13/2025Piper SandlerLower TargetOverweight ➝ Overweight$43.00 ➝ $30.00
1/10/2025WedbushReiterated RatingOutperform$12.00
1/10/2025HC WainwrightBoost TargetBuy ➝ Buy$14.00 ➝ $16.00
12/12/2024Raymond James FinancialInitiated CoverageOutperform$26.00
11/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
11/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
11/5/2024WedbushReiterated RatingOutperform$15.00 ➝ $12.00
10/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
10/25/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
9/30/2024WedbushReiterated RatingOutperform ➝ Outperform$15.00 ➝ $15.00
9/12/2024Stifel NicolausInitiated CoverageBuy$16.00
8/13/2024Jefferies Financial GroupReiterated RatingBuy ➝ Buy$16.00 ➝ $17.00
8/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
8/6/2024WedbushReiterated RatingOutperform$15.00
8/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
7/25/2024WedbushReiterated RatingOutperform ➝ Outperform$15.00 ➝ $15.00
7/2/2024WedbushReiterated RatingOutperform$15.00
7/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
5/30/2024Wells Fargo & CompanyInitiated CoverageOverweight$14.00
5/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00
5/7/2024WedbushReiterated RatingOutperform$15.00
4/9/2024Bank of AmericaLower TargetBuy ➝ Buy$16.00 ➝ $14.00
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00
4/8/2024WedbushReiterated RatingOutperform$15.00
3/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00
3/12/2024WedbushReiterated RatingOutperform$15.00
1/30/2024WedbushReiterated RatingOutperform ➝ Outperform$15.00
11/8/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00
11/7/2023WedbushReiterated RatingOutperform$15.00
9/27/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00
9/8/2023WedbushReiterated RatingOutperform ➝ Outperform$15.00
8/9/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00
8/8/2023WedbushReiterated RatingOutperform$15.00
8/4/2023HC WainwrightLower TargetBuy ➝ Buy$19.00 ➝ $16.00
7/27/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00
4/19/2023Needham & Company LLCReiterated RatingBuy$23.00
3/23/2023Jefferies Financial GroupUpgradeHold ➝ Buy$4.50 ➝ $6.00
3/22/2023WedbushReiterated RatingOutperform$15.00
2/17/2023Needham & Company LLCReiterated RatingBuy$23.00
2/17/2023HC WainwrightReiterated RatingBuy$20.00
5/26/2022Jefferies Financial GroupInitiated CoverageHold$5.00
5/10/2022WedbushLower TargetOutperform$25.00 ➝ $23.00
4/14/2022Needham & Company LLCInitiated CoverageBuy$23.00
3/16/2022WedbushLower TargetOutperform$35.00 ➝ $25.00
2/7/2022HC WainwrightInitiated CoverageBuy$33.00
11/29/2021Needham & Company LLCInitiated CoverageBuy$23.00
(Data available from 5/26/2021 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/26/2026

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Inozyme Pharma logo
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $4.00
Low: $4.00
High: $4.00

50 Day Range

MA: $3.99
Low: $3.95
High: $4.00

52 Week Range

Now: $4.00
Low: $0.93
High: $4.00

Volume

N/A

Average Volume

2,792,724 shs

Market Capitalization

$258.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Inozyme Pharma?

The following Wall Street analysts have issued research reports on Inozyme Pharma in the last year: Wall Street Zen.
View the latest analyst ratings for INZY.

What is the current price target for Inozyme Pharma?

0 Wall Street analysts have set twelve-month price targets for Inozyme Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Inozyme Pharma in the next year.
View the latest price targets for INZY.

What is the current consensus analyst rating for Inozyme Pharma?

Inozyme Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for INZY.

What other companies compete with Inozyme Pharma?

Other companies that are similar to Inozyme Pharma include Corvus Pharmaceuticals, Savara, Aktis Oncology, Cronos Group and Alvotech. Learn More about companies similar to Inozyme Pharma.

How do I contact Inozyme Pharma's investor relations team?

The company's listed phone number is 857-330-4340 and its investor relations email address is [email protected]. The official website for Inozyme Pharma is www.inozyme.com. Learn More about contacing Inozyme Pharma investor relations.